Sienna Cancer Diagnostics Limited announced audited consolidated earnings results for the year ended June 30, 2018. For the year, the company reported product revenue of AUD 527,845 compared to AUD 803,574 a year ago. Loss before income tax was AUD 2,182,194 compared to AUD 695,310 a year ago. Loss for period was AUD 2,182,194 compared to AUD 695,310 a year ago. Loss per basic and diluted share was AUD 0.01 compared to AUD 0.00 a year ago. Net cash used in operating activities was AUD 2,196,570 compared to AUD 792,807 a year ago. Purchase of intangibles was AUD 81,124 compared to AUD 56,741 a year ago. Purchase of property, plant and equipment was AUD 14,042 compared to AUD 13,193 a year ago.